According to the evaluation of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2/ERBB2/Neu), breast cancers are routinely divided into hormone receptor positive, HER-2/Neu amplified, and triple-negative breast cancer (TNBC) subtypes [2–4]. Here, ESR1 is linked to triple-negative breast carcinoma.